<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177082</url>
  </required_header>
  <id_info>
    <org_study_id>PXL-330-CAT</org_study_id>
    <nct_id>NCT04177082</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution</brief_title>
  <official_title>Evaluation of the Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions Using Peschke Riboflavin Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornea Associates of Texas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Associates of Texas</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in
      Eyes With Corneal Thinning Conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,
      visual acuity, pachymetry, and visual function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2029</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-Max</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in K-Max, compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>K-Mean</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in K-Mean, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in uncorrected visual acuity, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in best corrected visual acuity, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Pachymetry</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in central pachymetry, compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Keratoconus</condition>
  <condition>Pellucid Marginal Corneal Degeneration</condition>
  <condition>Corneal Degeneration</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed 6mW/cm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulsed 4mW/cm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Pulsed 4mW/cm2</arm_group_label>
    <arm_group_label>Pulsed 6mW/cm2</arm_group_label>
    <other_name>Corneal crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects who have one or both eyes that meet criteria 1-4 and also meet at least 1 or more
        of criteria 5-11 will be considered candidates for this study:

          1. 8 years of age or older

          2. Signed written informed consent

          3. Willingness and ability to comply with schedule for follow-up visits

          4. Contact Lens Wearers Only:

               1. Removal of contact lenses for the required period of time prior to the screening
                  refraction:

                  Contact Lens Type Minimum Discontinuation Time Soft 3 days Soft Extended Wear 3
                  days Soft Toric 3 days Rigid gas permeable 2 Weeks

               2. Subjects who cannot function without wearing their contact lenses, may forgo
                  discontinuation of contact lenses.

          5. Presence of central or inferior steepening.

          6. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid
             marginal degeneration

          7. Presence of one or more findings associated with keratoconus or pellucid marginal
             degeneration, such as:

               1. Fleischer ring

               2. Vogt's striae

               3. Decentered corneal apex

               4. Munson's sign

               5. Rizzutti's sign

               6. Apical Corneal scarring consistent with Bowman's breaks

               7. Scissoring of the retinoscopic reflex

               8. Crab-claw appearance on topography

          8. Steepest keratometry (Kmax) value â‰¥ 47.20 D

          9. I-S keratometry difference &gt; 1.5 D on the Pentacam/Orbscan map or topography map

         10. Posterior corneal elevation &gt;16 microns

         11. Thinnest corneal point &gt;300 microns
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyrone McCall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea Associates of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tyrone McCall, MD</last_name>
    <phone>214-692-0146</phone>
    <email>tmccall@corneatexas.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Seale, COT</last_name>
    <phone>214-692-0146</phone>
    <email>jseale@corneatexas.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cornea Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyrone McCall, MD</last_name>
      <phone>214-692-0146</phone>
      <email>tmccall@corneatexas.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Seale, COT</last_name>
      <phone>214-692-0146</phone>
      <email>jseale@corneatexas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tyrone McCall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Gelender, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter E Beebe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles B Bowman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Nettune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Zaffos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Alexander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luke Potts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be held in a secure location. While summary outcomes data will be provided on request to other researchers and periodically at scientific conferences, protected health information will not.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

